EMA freezes UK representatives out of drug reviews as Brexit loomsThe UK’s drugs regulator is increasingly being frozen out of work with the European Medicines Agency (EMA) according Share XEMA freezes UK representatives out of drug reviews as Brexit loomshttps://pharmaphorum.com/news/ema-freezes-uk-representatives-out-of-drug-reviews-as-brexit-looms/
Neurofibromatosis treatment granted orphan status by EMAAstraZeneca and Merck & Co. announced the European Medicines Agency (EMA) has granted orphan designation to their codeveloped Share XNeurofibromatosis treatment granted orphan status by EMAhttps://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/
EMA warns Brexit move will cause higher-than-expected staff lossesEurope’s medicines regulator is expecting higher-than-anticipated staff departures as a result of its Brexit-induced move from London to Share XEMA warns Brexit move will cause higher-than-expected staff losseshttps://pharmaphorum.com/news/ema-brexit-staff-losses-amsterdam/
UK pharma calls for cooperation as EMA continues Brexit splitBritain’s pharma trade body has issued a fresh Brexit warning, saying it would be disadvantageous to both the Share XUK pharma calls for cooperation as EMA continues Brexit splithttps://pharmaphorum.com/news/uk-pharma-calls-for-cooperation-as-ema-continues-brexit-split/
Dangerous inflammation prompts worldwide withdrawal of MS drugBiogen and AbbVie have announced the voluntary withdrawal of their multiple sclerosis drug Zinbryta from all markets worldwide Share XDangerous inflammation prompts worldwide withdrawal of MS drughttps://pharmaphorum.com/news/dangerous-inflammation-prompts-worldwide-withdrawal-ms-drug/
EU cancer drugs rejection shows contrasts with FDAEurope’s expert medicines panel has rejected Puma Biotechnology’s breast cancer drug neratinib, citing limitations in its efficacy and safety Share XEU cancer drugs rejection shows contrasts with FDAhttps://pharmaphorum.com/news/eu-rejection-cancer-drugs-shows-differences-fda/
Pharma looking for progress as Brexit talks restartPharma hoping for mutual recognition arrangement Share XPharma looking for progress as Brexit talks restarthttps://pharmaphorum.com/news/pharma-looking-progress-brexit-talks-restart/
Concerns over UK’s fading influence after EMA departureThis week’s decision to relocate the European Medicines Agency to Amsterdam has been greeted as the least damaging Share XConcerns over UK’s fading influence after EMA departurehttps://pharmaphorum.com/transversal-categories/healthcare/concerns-european-medicines-agency-relocation/
EMA’s post-Brexit location to be decided todayThe location of the European Medicines Agency after Brexit is to be decided today, as representatives of member Share XEMA’s post-Brexit location to be decided todayhttps://pharmaphorum.com/news/european-medicines-agency-relocation/